Thessaloniki

• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) Ended
  2022-502837-24-00 5 2023-09-25 Overweight
• A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Pa … Ended
  2023-508489-14-00 4 2023-09-18 Solid Tumors
• A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase … Ended
  2022-502833-25-00 5 2023-08-02 Obesity
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended
  2022-502234-70-00 5 2023-07-14 Chronic Obstructive Pulmonary Disease (COPD)
• ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended
  2022-501802-36-00 5 2023-06-16 Prevention of cardiac surgery associated acute kidney injury
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of c … Ended
  2024-518430-91-00 5 2023-06-13 Acne Vulgaris
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
• A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended
  2023-509746-35-00 4 2023-05-16 Primary Discoid Lupus Erythematosus
• A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS90 … Ended
  2022-501190-39-01 3 2023-05-15 Paroxysmal nocturnal hemoglobinuria
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11 Atopic Dermatitis
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended
  2023-508735-31-00 5 2023-05-05 Pulmonary Arterial Hypertension (PAH)
• A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin for the … Ended
  2024-516385-10-00 4 2023-05-02 Acute Bacterial Skin and Skin Structure Infections
• A Phase 2b study of TAK-755 (rADAMTS13) with minimal to no plasma exchange in the treatment of patients with thrombotic thrombocytopenic Pur … Ended
  2023-507787-39-00 4 2023-04-27 Immune-mediated thrombotic thrombocytopenic purpura (iTTP)
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended
  2023-507503-62-00 4 2023-03-30 Non-alcoholic Fatty Liver Disease
• Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of r … Ended
  2024-514677-22-00 5 2023-03-23 Restoration of sinus rhythm in patients with recent AF onset
• A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien … Ended
  2022-501363-40-00 3 2023-03-17 Advanced or metastatic solid tumors with a KRAS-G12C mutation
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Ended
  2023-504238-23-00 5 2023-01-17 Hepatitis B, Chronic
• Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus I … Ended
  2024-511755-18-00 5 2022-12-23 Invasive Candidiasis/ Candidemia
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck

Showing 553–576 of 652 trials